Pharmacology/Pharmaceutical Industry | Page 94 of 172 | Links Medicus Content Curation & Alerts in Medicine

Vaccines are here. We have to talk about side effects

18 Dec, 2020 | 09:59h | UTC

Vaccines Are Here. We Have to Talk About Side Effects – Wired

Commentary on Twitter

All vaccines have side effects and trust comes from freely discussing them. Nice piece by ⁦@marynmck⁩ https://t.co/eUISXTiFVP

— Madhu Pai, MD, PhD (@paimadhu) December 17, 2020

Studies warn of COVID vaccine access issues for low-income nations

18 Dec, 2020 | 09:54h | UTC

Studies warn of COVID vaccine access issues for low-income nations – CIDRAP

Study 1: Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis – The BMJ

Study 2: Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study – The BMJ

Editorial: Equitable global access to coronavirus disease 2019 vaccines – The BMJ

Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action

18 Dec, 2020 | 09:52h | UTC

Inclusion of pregnant women in COVID-19 treatment trials: a review and global call to action – The Lancet Global Health

Commentaries: Pregnant women excluded from three-quarters of COVID-19 treatment trials – The Lancet AND Expert reaction to opinion piece on pregnant women and COVID-19 treatment trials – Science Media Centre

Commentary on Twitter (thread – click for more)

NEW—Pregnant women are among those most in need of safe and effective therapies against #COVID19, but are routinely excluded from 3/4 of treatment trials. Read the review published in @LancetGH: https://t.co/xvBfHqnHMe @WHO pic.twitter.com/pBuTcsUZ0O

— The Lancet (@TheLancet) December 17, 2020

CDC Guidelines for Gonococcal Infection, 2020. CDC recommends a single 500 mg intramuscular dose of ceftriaxone for uncomplicated gonorrhea, with oral doxycycline for 7 days when chlamydial coinfection has not been excluded

18 Dec, 2020 | 09:40h | UTC

Update to CDC’s Treatment Guidelines for Gonococcal Infection, 2020 – Centers for Disease Control and Prevention

Commentary: CDC Guidelines Recommend Ceftriaxone Monotherapy for Uncomplicated Gonorrhea – NEJM Journal Watch

Commentary on Twitter

https://twitter.com/GarrettHile/status/1339732944613720064

Guideline: ADA 2021 Standards of Medical Care in Diabetes

10 Dec, 2020 | 00:11h | UTC

Just published! New ADA 2022 Guideline for the Management of Diabetes

Guideline Homepage: ADA 2021 Standards of Medical Care in Diabetes – American Diabetes Association (free supplement)

See ADA 2021 Guideline topics below:

Introduction: Standards of Medical Care in Diabetes—2021

Summary of Revisions: Standards of Medical Care in Diabetes—2021

Commentary on Twitter

ADA's "Standards of Medical Care in Diabetes—2021" is finally here! Featuring American Diabetes Association's latest clinical practice recommendations, the global standard for diabetes care. #ADASOC2021

📖 READ NOW (OPEN ACCESS): https://t.co/VyIT2yJnW8 pic.twitter.com/vOM5XXKLoU

— ADA Professional Publications (@ADA_Pubs) December 9, 2020

Comprehensive overview of current pharmacological augmentation recommendations for major depression

17 Dec, 2020 | 08:55h | UTC

Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines – The International Journal of Neuropsychopharmacology

Commentary on Twitter

Pharmacological augmentation in unipolar depression – our new review of treatment guidelines compares current recommendations and discusses future guideline development @LindseyMarwood @valeriadeangel @roland_zahn @TCleare @ijnp_neuropsych https://t.co/ui5mGUP8nW

— Rachael Taylor (@rachael_wallis) June 5, 2020

Video (5min): Ivermectin for COVID-19 | A Doctor Explains

16 Dec, 2020 | 09:43h | UTC

Ivermectin For COVID-19 | A Doctor Explains – ZDoggMD

Perspective: How Science Beat the Virus – And what it lost in the process

15 Dec, 2020 | 01:40h | UTC

How Science Beat the Virus – The Atlantic

Commentary from the author on Twitter (thread – click for more)

🚨I wrote the Atlantic’s next cover story on the COVIDization of science. No other disease has been scrutinized so intensely, by so much combined intellect, in so brief a time. This piece is about both the victories achieved & the weaknesses exposed. 1/ https://t.co/RbL9mVHhEv

— Ed Yong is not here (@edyong209) December 14, 2020

News Release: The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials

15 Dec, 2020 | 01:36h | UTC

The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials

[Preprint] RECOVERY trial: Azithromycin does not improve outcomes in hospitalized patients with COVID-19

15 Dec, 2020 | 01:44h | UTC

Azithromycin in Hospitalised Patients with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial – medRxiv

News release: RECOVERY trial finds no benefit from azithromycin in patients hospitalised with COVID-19

Commentary: Expert reaction to preprint from the RECOVERY trial on the antibiotic azithromycin in patients hospitalised with COVID-19, reporting no benefit – Science Media Centre

Commentary on Twitter

New RECOVERY result. In patients hospitalised with COVID-19, azithromycin did not provide any clinical benefit. 28 day mortality (19% vs 19%) (rate ratio 1·00; 95% confidence interval [CI] 0·90-1·12; p=0·99). No effect on secondary outcomes either.https://t.co/PTklz40WKr pic.twitter.com/NCzvRIND0S

— Peter Horby @peterhorby.bsky.social (@PeterHorby) December 14, 2020

Arab nations first to approve Chinese COVID vaccine — despite lack of public data

15 Dec, 2020 | 01:38h | UTC

Arab nations first to approve Chinese COVID vaccine — despite lack of public data – Nature

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

13 Dec, 2020 | 23:31h | UTC

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine

Commentary: Baricitinib plus remdesivir shows promise for treating COVID-19 – NIH News Releases

Commentary on Twitter

Not sure how to interpret a trial for a drug plus Remdesivir vs Remdesivir alone when you don't know if Remdesivir works. @NEJM today for this combo, which has already received FDA EUAhttps://t.co/tpmHPFPJX1 pic.twitter.com/Tmue99oJnV

— Eric Topol (@EricTopol) December 11, 2020

Meta-analysis: Efficacy and harms of remdesivir for the treatment of COVID-19. “Until stronger evidence emerges, we cannot conclude that remdesivir is efficacious for treating COVID-19”.

13 Dec, 2020 | 23:27h | UTC

Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis – PLOS One

Video: Coronavirus vaccine update with Anthony Fauci

13 Dec, 2020 | 23:25h | UTC

Coronavirus Vaccine Update With Anthony Fauci – JAMA

A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19 – corticosteroid treatment is not recommended for patients with mild or moderate COVID-19

13 Dec, 2020 | 23:26h | UTC

A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19 – Scientific Reports

A doctor on 9 things that could go wrong with the new vaccines – by worrying together, we can prevent much of this from happening

13 Dec, 2020 | 23:21h | UTC

A doctor on 9 things that could go wrong with the new vaccines – Vox

WHO calls on world leaders to “honor their pledge” to fund COVID-19 vaccines; South Africa raises specter of “vaccine apartheid”

13 Dec, 2020 | 23:22h | UTC

WHO Calls On World Leaders To “Honor Their Pledge” To Fund COVID-19 Vaccines; South Africa Raises Spectre Of “Vaccine Apartheid” – Health Policy Watch

Systematic review: Among patients with advanced chronic kidney disease and uremic pruritus, gabapentinoids are the most studied treatments and show the greatest reduction in itch scores

13 Dec, 2020 | 23:16h | UTC

Interventions for itch in people with advanced chronic kidney disease – Cochrane Library

Commentary: What is the best treatment for itch in people with chronic kidney disease? – Cochrane Library

Just published: Pfizer vaccine confers 95% protection against Covid-19

11 Dec, 2020 | 09:32h | UTC

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine – New England Journal of Medicine

Editorial: SARS-CoV-2 Vaccination — An Ounce (Actually, Much Less) of Prevention

Commentary: Pfizer vaccine results published in peer-reviewed journal – MedicalXpress

Commentary on Twitter (Thread – Click for more)

I read the @pfizer @US_FDA vaccine briefing doc

3 take homes (1 obvious, 2 new takes I haven't seen before)

1. Efficacy is great to prevent #COVID19 & promising for severe illness (this has been said many times before)

Moving on…https://t.co/WLrEpjmuO8

— Anil Makam (@AnilMakam) December 10, 2020

Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis

13 Dec, 2020 | 23:12h | UTC

Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis – Gastroenterology

Editorial: Maintenance Topical Steroid Therapy in Eosinophilic Esophagitis: Not So Hard to Swallow Any More?

Commentary: Budesonide for Maintaining EoE Remission – gutsandgrowth

Commentary on Twitter

In a phase 3 trial, up to 48 weeks of treatment with BOT was superior to placebo in maintaining remission of #EoE https://t.co/vewrFYgIG9 pic.twitter.com/P1DzdWb2vH

— Gastroenterology (@AGA_Gastro) November 25, 2020

Randomized trial: Long-acting injectable antipsychotic use by patients with early-phase schizophrenia can significantly delay time to first hospitalization

11 Dec, 2020 | 09:14h | UTC

Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial – JAMA Psychiatry

Commentary: Long-Acting Injectable Antipsychotics vs. Usual Care for Early-Phase Schizophrenia – Physician’s Weekly

Commentary on Twitter

RCT: The mean survival time until 1st hospitalization was 613.7 days for patients with schizophrenia treated with aripiprazole once monthly vs. 530.6 days for those treated with usual care (HR=0.56; 0.34- 0.92; NNT=7) https://t.co/i3857D2ULQ

— P𝘧OL (@psychopharmacol) December 5, 2020